Molecular Templates, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements (Tables)

Research and Development Agreements (Tables)

6 Months Ended

Jun. 30, 2019

Schedule of Research and Development Revenues Disaggregated by Location

Research and development revenue is attributable to regions based on the location of our collaboration partner's parent company headquarters. Research and development revenues disaggregated by location were as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Japan	$	5,211	$	932	$	11,624	$	1,095
United States		—		12		—		80
Total research and development revenue	$	5,211	$	944	$	11,624	$	1,175

Takeda Pharmaceuticals Inc

Schedule of Research and Development Revenue from Related Party Relates to Revenue from Research and Development Agreements

Research and development revenue from related party relates to revenue from research and development agreements with Takeda Pharmaceuticals, Inc (“Takeda”) and were as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Takeda Collaboration Agreement	$	—	$	81	$	—	$	92
Takeda Individual Project Agreement		—		663		54		663
Takeda Development and License Agreement		5,012		—		11,126		—
Takeda Multi-Target Agreement		199		188		444		340
Total research and development revenue	$	5,211	$	932	$	11,624	$	1,095

Schedule of Deferred Revenue and Accounts Receivable Balances from the Research and Development Agreements

Deferred revenue and accounts receivable balances from the research and development agreements with Takeda were as follows (in thousands):

	June 30, 2019		December 31, 2018
Assets
Unbilled revenue	$	—	$	240
Liabilities
Deferred revenue, current	$	14,561	$	26,231
Deferred revenue, non-current		1,664		2,670
Total deferred revenue	$	16,225	$	28,901